Cargando…

Targeting Therapeutic Antibodies to the CNS: a Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats

Antibody-based therapeutics targeting CNS antigens emerge as promising treatments in neurology. However, access to the CNS is limited by the blood–brain barrier. We examined the effects of a neurite growth-enhancing anti-Nogo A antibody therapy following 3 routes of administration—intrathecal (i.t.)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wahl, Anna-Sophia, Correa, Daphne, Imobersteg, Stefan, Maurer, Michael Andreas, Kaiser, Julia, Augath, Marc Aurel, Schwab, Martin E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609675/ https://www.ncbi.nlm.nih.gov/pubmed/32378027 http://dx.doi.org/10.1007/s13311-020-00864-z

Ejemplares similares

Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets
por: Correa, Daphne, et al.
Publicado: (2023)

Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke
por: Rust, Ruslan, et al.
Publicado: (2019)

Nogo-A antibody delivery through the olfactory mucosa mitigates experimental autoimmune encephalomyelitis in the mouse CNS
por: Pernet, Vincent, et al.
Publicado: (2023)

A Comparison of Subcutaneous with Intravenous and Intrathecal Administration of Tetanus Antitoxin in Experimental Tetanus
Publicado: (1918)

Anti-NOGO Antibody Neuroprotection in a Rat Model of NAION
por: Johnson, Mary A., et al.
Publicado: (2021)

The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration
por: Georgieva, Julia V., et al.
Publicado: (2022)

Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates
por: Gray, Steven J., et al.
Publicado: (2013)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Intrathecal B-cell activation in LGI1 antibody encephalitis
por: Lehmann-Horn, Klaus, et al.
Publicado: (2020)

Application of Antibodies to Neuronally Expressed Nogo-A Increases Neuronal Survival and Neurite Outgrowth
por: Nagaraj, Vini, et al.
Publicado: (2020)

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
por: Matucci, Andrea, et al.
Publicado: (2018)

Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model
por: Falck, David, et al.
Publicado: (2022)

CHRONIC ENCEPHALOMYELITIS WITH SPECIFIC INCREASE IN INTRATHECAL MUMPS ANTIBODIES
por: Vaheri, Antti, et al.
Publicado: (1982)

Antibody-mediated inhibition of Nogo-A signaling promotes neurite growth in PC-12 cells
por: Yazdi, Iman K, et al.
Publicado: (2016)

Nogo-A-targeting antibody promotes visual recovery and inhibits neuroinflammation after retinal injury
por: Baya Mdzomba, Julius, et al.
Publicado: (2020)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination
por: Kinzel, Silke, et al.
Publicado: (2017)

Intravenous Immunoglobulin Treatment Did Not Improve Tics in a Patient With Gilles de la Tourette Syndrome and Intrathecal Antibody Synthesis
por: Szejko, Natalia, et al.
Publicado: (2020)

Anti-Nogo-A antibody treatment does not prevent cell body shrinkage in the motor cortex in adult monkeys subjected to unilateral cervical cord lesion
por: Beaud, Marie-Laure, et al.
Publicado: (2008)

Nogo-A and Nogo-66 receptor in amyotrophic lateral sclerosis
por: Teng, Felicia Yu Hsuan, et al.
Publicado: (2008)

Intrathecal cytokine profile in neuropathy with anti‐neurofascin 155 antibody
por: Ogata, Hidenori, et al.
Publicado: (2019)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates – re-examination and extension of behavioral data
por: Freund, Patrick, et al.
Publicado: (2009)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022)

Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional ‘detour’ in the hemisected spinal cord
por: Schnell, Lisa, et al.
Publicado: (2011)

Combined with anti‐Nogo‐A antibody treatment, BDNF did not compensate the extra deleterious motor effect caused by large size cervical cord hemisection in adult macaques
por: Beaud, Marie‐Laure, et al.
Publicado: (2019)

Nogo-A Downregulation Improves Insulin Secretion in Mice
por: Bonal, Claire B., et al.
Publicado: (2013)

Nogo-A Regulates Neural Precursor Migration in the Embryonic Mouse Cortex
por: Mathis, Carole, et al.
Publicado: (2010)

Anti-Nogo-A antibody promotes brain function recovery after cardiopulmonary resuscitation in rats by reducing apoptosis
por: Wu, Qinqin, et al.
Publicado: (2020)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
por: Kim, Sung-Min, et al.
Publicado: (2015)

Influence of anti-Nogo-A antibody treatment on the reorganization of callosal connectivity of the premotor cortical areas following unilateral lesion of primary motor cortex (M1) in adult macaque monkeys
por: Hamadjida, Adjia, et al.
Publicado: (2012)

Experience-dependent expression of Nogo-A and Nogo receptor in the developing rat visual cortex
por: Wu, Xiaoying, et al.
Publicado: (2012)

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
por: Kroesen, B. J., et al.
Publicado: (1994)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis
por: Fialová, Lenka, et al.
Publicado: (2011)

Intrathecal immunoglobulin A and G antibodies to synapsin in a patient with limbic encephalitis
por: Piepgras, Johannes, et al.
Publicado: (2015)

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
por: Gamage, S. M. K., et al.
Publicado: (2018)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery
por: Kagiava, A., et al.
Publicado: (2021)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pmbpnn4pon8hc8uem1f9jjfqms